Filing Details
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) filed a Form 8-K with the Securities and Exchange Commission on July 10, 2026, disclosing a material event.
8k filedNASDAQ:ZVSA
ZyVersa Therapeutics, Inc. (ZVSA) Reports Material Event to SEC
Filing Details ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) filed a Form 8-K with the Securities and Exchange Commission on July 10, 2026, disclosing a material event. Market Context…
Market Context
ZyVersa Therapeutics, Inc.'s stock currently trades at $0.12 with a market capitalization of $1.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ZyVersa Therapeutics, Inc.'s stock.
All SEC filings for ZyVersa Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ZVSA Stock Page
Frequently Asked Questions
Where can I read ZVSA's SEC filings?
Browse all filings on our ZVSA SEC filings page.
What types of SEC filings does ZyVersa Therapeutics, Inc. file?
Public companies like ZyVersa Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.